Daytime intragastric acid control: <i>post hoc</i> analyses of esomeprazole 20 mg and over-the-counter proton-pump inhibitors
Philip O. Katz(Cornell University), John Dent(Royal Adelaide Hospital), Vincent Hugo(Pfizer (United States)), Barry Traxler(AstraZeneca (United States)), Peter J. Kahrilas(Northwestern University), Tore Lind(Skaraborg Hospital), David A. Johnson(University of Chicago), Kerstin Röhss(AstraZeneca (Sweden))
Cited by 6
Related Papers
Capecitabine compared with observation in resected biliary tract cancer (BILCAP): a randomised, controlled, multicentre, phase 3 study
|The Lancet Oncology|2019|1.2k
ACCF/ACG/AHA 2008 Expert Consensus Document on Reducing the Gastrointestinal Risks of Antiplatelet Therapy and NSAID Use
|Circulation|2008|845
Healing and relapse of severe peptic esophagitis after treatment with omeprazole
|Gastroenterology|1988|786